The Impact of COVID-19 Pandemic on Surgical Treatment of Resectable Non-Small Cell Lung Cancer in Greece

Tomos, Ioannis; Kapetanakis, Emmanouil I.; Dimakopoulou, Konstantina; Raptakis, Thomas; Kampoli, Katerina; Karakatsani, Anna; Klinke, Anna; Papiris, Spyros; Tomos, Periklis

doi:10.3390/life13010218

Cited by 9 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Enlargement of primary lesions and progression of cancers discovered during the COVID-19 epidemic have been confirmed (15)(16)(17)(18)(19)(20)(21)(22). In breast cancer, for example, an increase in tumor size (15)(16)(17)(18)(19) and the of patients with advanced stage (17)(18)(19) has been reported.…”

Section: Discussionmentioning

confidence: 84%

“…In breast cancer, for example, an increase in tumor size (15)(16)(17)(18)(19) and the of patients with advanced stage (17)(18)(19) has been reported. In patients with resectable NSCLC, there were some reports of increased primary tumor diameter during the COVID-19 pandemic, although no differences were found in clinical stage (20)(21)(22). To our best knowledge, however, no study has assessed tumor size in advanced NSCLC during the COVID-19 pandemic and confirmed that they were diagnosed with greater size.…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

Impact of COVID-19 Pandemic on Advanced Non-small Cell Lung Cancer Treatment at a Japanese Hospital

MIYAZAKI,

KODAMA,

AIDA

et al. 2023

CDP

View full text Add to dashboard Cite

Background/Aim: The COVID-19 pandemic has forced medical institutions to scale back their practice. Changes in patient behavior seemed to be having an impact. We conducted a survey with the aim of reviewing lung cancer treatment during the pandemic period and identifying problems. Patients and Methods: We examined the medical records of all patients pathologically diagnosed with non-small cell lung cancer (NSCLC) in our hospital from 2017 to 2022. NSCLC patients were divided into two groups: those diagnosed between 2017 and 2019 (first period) and those diagnosed between 2020 and 2022 (second period). Results: Within the study period, 267 NSCLC patients (first period: 147 patients, second period: 121 patients) were diagnosed in our hospital. The patients in the two study periods did not differ significantly in age (p=0.613), ECOG performance status (p=0.125), and clinical stage (p=0.354). Tumor size was significantly larger in the second period with a mean of 5.88 cm ± 3.02, compared to 4.24 cm ± 1.76 in the first period (p<0.001). In the standard treatment group, the median survival time was 457 days in the first period and 313 days in the second period (p=0.063). In the best supportive care group, median survival time was 122 days in the first period and 57 days in the second period (p=0.004). Conclusion: Patients themselves refrained from seeking consultation for lung cancer treatment during the pandemic period. It is inconclusive how to reduce the delay due to the suppression of consultations, but this is an important issue for the future.

show abstract

Section: Discussionmentioning

confidence: 84%

Section: Discussionmentioning

confidence: 92%

Impact of COVID-19 Pandemic on Advanced Non-small Cell Lung Cancer Treatment at a Japanese Hospital

MIYAZAKI,

KODAMA,

AIDA

et al. 2023

CDP

View full text Add to dashboard Cite

show abstract

“…In studies that stratified by treatment type, studies from Germany, Austria, Spain, and the Netherlands reported between 21% and 31% of patients experiencing delays for follow‐up visits; 15,28‐30 studies from India, Germany, and China reported 9% to 52% patients experiencing cancer surgery delays; 9,10,29,32 and, studies from Spain, Italy, India, and China reported between 23% to 38% patients reporting delays in radiotherapy 8,28,32,33 . Additionally, a majority of patients in three studies reported differences in median time to surgery during the pandemic compared to before the pandemic in the U.K. and Greece 34,35 . This consistency demonstrated in national and global findings indicates the importance of addressing cancer care delays and in opportunities for learning from solutions identified in different global contexts.…”

Section: Discussionmentioning

confidence: 99%

Identifying predictors of COVID‐related delays in cancer‐specific medical care

Greteman,

Del Vecchio,

Garcia‐Auguste

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

PurposeEvidence of the impact of the COVID‐19 pandemic on cancer prevention and control is growing, but little is known about patient‐level factors associated with delayed care. We analyzed data from a survey focused on Iowan cancer patients' COVID‐19 experiences in the early part of the pandemic.MethodsParticipants were recruited from the University of Iowa Holden Comprehensive Cancer Center's Patients Enhancing Research Collaborations at Holden (PERCH) program. We surveyed respondents on demographic characteristics, COVID‐19 experiences and reactions, and delays in any cancer‐related health care appointment, or cancer‐related treatment appointments. Two‐sided significance tests assessed differences in COVID‐19 experiences and reactions between those who experienced delays and those who did not.ResultsThere were 780 respondents (26% response), with breast, prostate, kidney, skin, and colorectal cancers representing the majority of respondents. Delays in cancer care were reported by 29% of respondents. In multivariable‐adjusted models, rural residents (OR 1.47; 95% CI 1.03, 2.11) and those experiencing feelings of isolation (OR 2.18; 95% CI 1.37, 3.47) were more likely to report any delay, where experiencing financial difficulties predicted delays in treatment appointments (OR 5.72; 95% CI 1.96, 16.67). Health insurance coverage and concern about the pandemic were not statistically significantly associated with delays.ConclusionThese findings may inform cancer care delivery during periods of instability when treatment may be disrupted by informing clinicians about concerns that patients have during the treatment process. Future research should assess whether delays in cancer care impact long‐term cancer outcomes and whether delays exacerbate existing disparities in cancer outcomes.

show abstract

“…First, unlike other models like the Non small cell lung cancer (NSCLC), we did not see the difference in tumor size ( p = 0.4454), depth ( p = 0.2042) and the presence of metastasis ( p = 0.5739) between 2019 and 2020. 5 In 2020, we observed a direct referral of patients for care to labeled centers, with a corollary of improved quality of care indicators. By contrast, the proportion of cases directly managed in labeled centers increased in the same year.…”

Section: Discussionmentioning

confidence: 99%

Impact of the coronavirus disease 2019 pandemic on sarcoma management in France: a 2019 and 2020 comparison

Penel,

Cantarel,

Chemin-Airiau

et al. 2023

Ther Adv Med Oncol

View full text Add to dashboard Cite

Background: The coronavirus disease 2019 (COVID-19) pandemic was an unprecedented shock to the healthcare systems, and its consequences on managing rare cancers are unknown. We investigated COVID-19’s impact on the activity of sarcoma-labeled networks by comparing key indicators in 2019–2020 (before and during the pandemic, respectively). Methods: We compared the incidence of limb and trunk soft tissue sarcomas, surgery rate, surgery center, surgery quality, and surgery delays nationally and in various regions, focusing on the three most severely affected regions. Findings: In this study, sarcoma incidence did not decrease, and the tumor and patient characteristics were similar in both years. The number of patients who underwent surgery in the labeled centers increased significantly (63% versus 57%, p = 0.015), the rate of R0 resection increased (55% versus 47%, p = 0.004), and the rate of re-excision decreased (12% versus 21%, p < 0.0001). In the univariate analysis, the time to surgery was similar in both years. Cox regression analysis revealed that the factors associated with a longer time to surgery were age > 70 years ( p = 0.003), retroperitoneal location ( p > 0.001), tumor size ( p < 0.001), deep tumors ( p < 0.001), and regions ( p < 0.001). However, we have observed an increase in the time before surgery in the regions most stroked by the COVID-19 pandemic. Interpretation: The model of the labeled center network for managing rare tumors was resilient. Paradoxically, the quality indicators improved during the pandemic due to the direct referral of patients with sarcomas to the labeled centers. Summary: This study shows that a nationwide network organization has made it possible to maintain care for these rare tumors during the pandemic.

show abstract

The Impact of COVID-19 Pandemic on Surgical Treatment of Resectable Non-Small Cell Lung Cancer in Greece

Cited by 9 publications

References 31 publications

Impact of COVID-19 Pandemic on Advanced Non-small Cell Lung Cancer Treatment at a Japanese Hospital

Impact of COVID-19 Pandemic on Advanced Non-small Cell Lung Cancer Treatment at a Japanese Hospital

Identifying predictors of COVID‐related delays in cancer‐specific medical care

Impact of the coronavirus disease 2019 pandemic on sarcoma management in France: a 2019 and 2020 comparison

Contact Info

Product

Resources

About